Werkgroep Cardiologische centra Nederland English

SPIRE-LL (Klaar)

A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Middel
PF-04950615 (PCSK9)
Populatie
preventie (cholesterol)
Fase
III
Jaar aanvang
2014
Meer informatie
clinicaltrials.gov